96 related articles for article (PubMed ID: 21804582)
21. Targeting endocrine resistance: is there a role for mTOR inhibition?
Sheri A; Martin LA; Johnston S
Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S79-85. PubMed ID: 21115426
[TBL] [Abstract][Full Text] [Related]
22. Epigallocatechin gallate (EGCG), a major component of green tea, is a dual phosphoinositide-3-kinase/mTOR inhibitor.
Van Aller GS; Carson JD; Tang W; Peng H; Zhao L; Copeland RA; Tummino PJ; Luo L
Biochem Biophys Res Commun; 2011 Mar; 406(2):194-9. PubMed ID: 21300025
[TBL] [Abstract][Full Text] [Related]
23. [Correlation of PI3K-Akt signal pathway to apoptosis of tumor cells].
Huang XL; Cui GH; Zhou KY
Ai Zheng; 2008 Mar; 27(3):331-6. PubMed ID: 18334129
[TBL] [Abstract][Full Text] [Related]
24. PI3K-FRAP/mTOR pathway is critical for hepatocyte proliferation whereas MEK/ERK supports both proliferation and survival.
Coutant A; Rescan C; Gilot D; Loyer P; Guguen-Guillouzo C; Baffet G
Hepatology; 2002 Nov; 36(5):1079-88. PubMed ID: 12395317
[TBL] [Abstract][Full Text] [Related]
25. Drug discovery approaches targeting the PI3K/Akt pathway in cancer.
Garcia-Echeverria C; Sellers WR
Oncogene; 2008 Sep; 27(41):5511-26. PubMed ID: 18794885
[TBL] [Abstract][Full Text] [Related]
26. Hispidulin, a small flavonoid molecule, suppresses the angiogenesis and growth of human pancreatic cancer by targeting vascular endothelial growth factor receptor 2-mediated PI3K/Akt/mTOR signaling pathway.
He L; Wu Y; Lin L; Wang J; Wu Y; Chen Y; Yi Z; Liu M; Pang X
Cancer Sci; 2011 Jan; 102(1):219-25. PubMed ID: 21087351
[TBL] [Abstract][Full Text] [Related]
27. The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer.
Castaneda CA; Cortes-Funes H; Gomez HL; Ciruelos EM
Cancer Metastasis Rev; 2010 Dec; 29(4):751-9. PubMed ID: 20922461
[TBL] [Abstract][Full Text] [Related]
28. Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT.
Svejda B; Kidd M; Kazberouk A; Lawrence B; Pfragner R; Modlin IM
Cancer; 2011 Sep; 117(18):4141-54. PubMed ID: 21387274
[TBL] [Abstract][Full Text] [Related]
29. Class IA phosphatidylinositol 3-kinase signaling in non-small cell lung cancer.
Solomon B; Pearson RB
J Thorac Oncol; 2009 Jul; 4(7):787-91. PubMed ID: 19550242
[No Abstract] [Full Text] [Related]
30. Mammalian target of rapamycin, Akt, and phosphatidylinositol 3-kinase signaling.
Pal SK; Reckamp KL
J Thorac Oncol; 2010 Dec; 5(12 Suppl 6):S487-9. PubMed ID: 21102251
[No Abstract] [Full Text] [Related]
31. Clinical development of voxtalisib: a pan-PI3K/mTOR inhibitor.
Munakata W; Tobinai K
Lancet Haematol; 2018 Apr; 5(4):e134-e135. PubMed ID: 29550380
[No Abstract] [Full Text] [Related]
32. Potential value and limitation of dual inhibitors of PI3K and mTOR in the treatment of cancer.
Chen J
Curr Cancer Drug Targets; 2013 Feb; 13(2):117-20. PubMed ID: 23215718
[No Abstract] [Full Text] [Related]
33. Are we AKT-ually getting closer to making targeted therapy successful in breast cancer brain metastases?
Majd N; Weathers SP; de Groot J
Neuro Oncol; 2019 Nov; 21(11):1344-1345. PubMed ID: 31515554
[No Abstract] [Full Text] [Related]
34. B lymphoma Moloney murine leukemia virus insertion region 1 homolog: the Janus-faced polycomb protein that will break your heart.
McCarthy CG; Wenceslau CF; Joe B
Am J Physiol Heart Circ Physiol; 2019 Feb; 316(2):H257-H259. PubMed ID: 30461305
[No Abstract] [Full Text] [Related]
35. Targeted PI3K inhibitors reduce lung fibrosis in mice.
Cully M
Nat Rev Drug Discov; 2020 Dec; 19(12):838. PubMed ID: 33122814
[No Abstract] [Full Text] [Related]
36. Opioids for the relief of acute respiratory distress syndrome: Endomorphins are the μ kids on the block!
Lucking EF; O'Halloran KD
Exp Physiol; 2019 Oct; 104(10):1445-1446. PubMed ID: 31389080
[No Abstract] [Full Text] [Related]
37. PI3K and cancer: lessons, challenges and opportunities.
Fruman DA; Rommel C
Nat Rev Drug Discov; 2014 Feb; 13(2):140-56. PubMed ID: 24481312
[TBL] [Abstract][Full Text] [Related]
38. PI3K signalling: the path to discovery and understanding.
Vanhaesebroeck B; Stephens L; Hawkins P
Nat Rev Mol Cell Biol; 2012 Feb; 13(3):195-203. PubMed ID: 22358332
[TBL] [Abstract][Full Text] [Related]
39.
Xu JM; Wang Y; Wang YL; Wang Y; Liu T; Ni M; Li MS; Lin L; Ge FJ; Gong C; Gu JY; Jia R; Wang HF; Chen YL; Liu RR; Zhao CH; Tan ZL; Jin Y; Zhu YP; Ogino S; Qian ZR
Clin Cancer Res; 2017 Aug; 23(16):4602-4616. PubMed ID: 28424201
[No Abstract] [Full Text] [Related]
40. Predictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway.
Tufail M; Hu JJ; Liang J; He CY; Wan WD; Huang YQ; Jiang CH; Wu H; Li N
J Transl Med; 2024 Jan; 22(1):15. PubMed ID: 38172946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
